BC2059

• CAT Number: I004090
• CAS Number: 1227637-23-1
• Molecular Formula: C28H36N4O6S2
• Molecular Weight: 588.74
• Purity: ≥95%
• Synonyms: (9E,10E)-2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime
• Target: β-Catenin Inhibitor
• Solubility: Soluble in DMSO, not in water
• Storage: 2-8°C
• IUPAC Name: N-[3,6-bis[[(3R,5S)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine
• InChI: InChI=1S/C28H36N4O6S2/c1-17-9-18(2)14-31(13-17)39(35,36)21-5-7-23-25(11-21)28(30-34)26-12-22(6-8-24(26)27(23)29-33)40(37,38)32-15-19(3)10-20(4)16-32/h5-8,11-12,17-20,29,33H,9-10,13-16H2,1-4H3/t17-,18+,19-,20+
• InChIKey: OMWCXCBGEFHCTN-FGYAAKKASA-N
• SMILES: CC1CC(CN(C1)S(=O)(=O)C2=CC3=C(C=C2)C(=C4C=CC(=CC4=C3N=O)S(=O)(=O)N5CC(CC(C5)C)C)NO)C

BC2059 is a selective and potent inhibitor of the Janus kinase 2 (JAK2) enzyme, a key regulator in the JAK/STAT signaling pathway. By inhibiting JAK2, BC2059 disrupts downstream signaling processes that contribute to the proliferation of abnormal hematopoietic cells in various malignancies, including myeloproliferative disorders. Its specificity for JAK2 over other JAK family members makes it a promising therapeutic agent for targeted treatment of cancers associated with dysregulated JAK2 signaling.